Medibank Private (ASX:MPL) is one of Australia's largest private health insurers, providing resident and non-resident health cover through the Medibank and ahm brands while also expanding into healthcare services through Medibank Health. Its FY26 result showed higher statutory and underlying earnings, an increased Dividend and continued growth in its healthcare services business, while FY27 guidance points to broadly stable resident Health Insurance margins rather than further Margin expansion.

FY26 Profit Increases as Revenue Continues to Grow

For the year ended 30 June 2026, Medibank reported statutory net profit after tax of $638.7 million, an increase of 27.5 per cent from the prior year.

Underlying net profit after tax was $636.8 million, representing growth of 2.9 per cent.

The difference between statutory and underlying Earnings reflects the treatment of items that are not considered part of ordinary operating performance.

Group revenue reached $9,115.2 million, up 5.9 per cent, while group operating profit increased 6.7 per cent to $813.5 million.

Operating expenses rose 7.1 per cent during the year. Medibank also reported $10 million of productivity savings, highlighting the importance of cost control as expenses and claims continue to rise.

Higher Dividend Reflects Underlying Earnings and Capital Position

Medibank declared a fully franked final dividend of 10.9 cents per share.

This took the total FY26 dividend to 19.2 cents per share, representing an increase of 6.7 per cent.

The final dividend had an ex-dividend date of 2 September 2026 and a Record Date of 3 September 2026, with payment scheduled for 8 October 2026.

The full-year dividend represented 83.0 per cent of underlying profit, placing the payout within Medibank's target range of 75 to 85 per cent.

The higher dividend was therefore supported by the group's underlying earnings and capital position while remaining within its stated payout framework.

Resident Policyholder Growth Remains Positive

Net resident policyholders increased by 22,100 during FY26, representing growth of 1.1 per cent.

Non-resident policy units declined by 2.3 per cent.

The differing trends highlight the importance of resident health insurance to Medibank's core operating performance.

During the year, Medibank paid $6.9 billion in claims, while resident claims growth per policy unit was 2.6 per cent.

Claims growth is a key determinant of health insurance profitability because insurers must balance premium revenue against the cost of medical benefits paid to policyholders.

The relationship between premium increases, policyholder growth and claims Inflation will therefore remain central to Medibank's margin performance in FY27.

FY27 Margin Guidance Points to Stability Rather Than Expansion

Medibank has indicated that resident health insurance gross margins are expected to remain broadly consistent with FY26 levels during FY27.

This guidance suggests that the company is not assuming a material expansion in margins despite ongoing revenue and policyholder growth.

Margins can be affected by several factors, including claims inflation, premium pricing, competition and changes in policyholder mix.

For Medibank Private (ASX:MPL), maintaining broadly stable margins while managing higher healthcare costs will be an important measure of operating discipline during FY27.

The guidance also means that earnings growth may increasingly depend on policyholder growth, cost control and contributions from businesses outside the core resident insurance operation.

Medibank Health Continues to Expand

Medibank Health delivered segment profit of $100.7 million in FY26, representing growth of 31.3 per cent.

The division provides healthcare services including telehealth, home care and other forms of healthcare delivery.

It represents Medibank's main avenue for Diversification beyond traditional private health insurance premiums.

For FY27, management expects Medibank Health segment profit to grow by approximately 25 per cent, including a full-year contribution from BetterMedical.

That guidance places greater importance on the division's ability to integrate acquired businesses and maintain earnings growth.

Continued expansion of Medibank Health could gradually increase the contribution of healthcare services to group earnings, although the division remains smaller than the core Health Insurance business.

Capital Position Remains Above Target Range

The Health Insurance required capital ratio was 13.3 per cent at the end of FY26.

This was above Medibank's target range of 10 to 12 per cent.

The elevated ratio included the effect of a temporary $250 million supervisory adjustment imposed by the prudential regulator.

Capital coverage stood at 1.9 times the prudential capital requirement.

Capital strength remains important because it supports the insurer's ability to absorb unexpected claims or operating costs while funding dividends and potential acquisitions.

Medibank has also indicated that it retains a pipeline of Acquisition opportunities and sufficient capacity to pursue selected transactions.

Any future acquisitions would need to be balanced against the group's existing capital requirements and integration priorities.

Cyber-Related Costs Remain a Legacy Issue

Medibank recorded $34.9 million of non-recurring costs in FY26 associated with the 2022 cyber incident.

These costs included spending on security upgrades as well as regulatory and legal matters.

For FY27, the company expects cyber-related non-recurring costs to fall below $20 million.

A reduction in these expenses would lessen one source of non-core cost pressure, although legal and regulatory outcomes remain uncertain.

Cybersecurity remains operationally important because Medibank handles significant volumes of sensitive customer and health-related information.

The company therefore continues to face both direct technology costs and broader compliance requirements associated with maintaining security controls.

Key Risks and Areas to Monitor

Claims inflation remains one of the most important risks to Medibank's earnings.

If claims costs rise faster than premiums, health insurance margins can come under pressure. Competition for policyholders may also affect pricing and retention.

The company's guidance for broadly stable resident margins means disciplined pricing and claims management will remain important through FY27.

Growth in Medibank Health also carries execution risk. The division's expected profit growth depends partly on integrating acquired businesses, including the full-year contribution from BetterMedical.

Future acquisitions could introduce additional integration and capital allocation considerations.

Cyber-related legal and regulatory matters remain another source of uncertainty, even though associated non-recurring costs are expected to decline.

What to Watch in FY27

The scheduled payment of the final dividend on 8 October 2026 is the next immediate corporate milestone.

Beyond that, policyholder growth, claims inflation and resident insurance margins will be important measures of whether the core insurance Business is tracking in line with FY27 expectations.

The performance of Medibank Health will also be closely watched against management's expectation for approximately 25 per cent segment profit growth.

The FY27 half-year result should provide a clearer indication of whether resident margins remain broadly stable, whether cyber-related costs are declining as expected and whether Medibank Health is delivering the anticipated contribution.

For Medibank Private (ASX:MPL), FY26 demonstrated continued earnings and dividend growth. FY27 will place greater emphasis on maintaining insurance margins while expanding healthcare services and managing cost pressures.